
Sign up to save your podcasts
Or


For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.
All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.
Disclosure information is available at the beginning of the video presentation.
By PVI, PeerView Institute for Medical Education4.5
1010 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.
All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.
Disclosure information is available at the beginning of the video presentation.

1,829 Listeners

318 Listeners

40 Listeners

27 Listeners

10 Listeners

528 Listeners

5 Listeners

3 Listeners

2 Listeners

5 Listeners

2 Listeners

3 Listeners

5 Listeners

5 Listeners

2 Listeners

0 Listeners

9 Listeners

2 Listeners

118 Listeners

11 Listeners

2 Listeners

4 Listeners

58 Listeners

3 Listeners

5 Listeners

291 Listeners

22 Listeners

196 Listeners

54 Listeners

58 Listeners

48 Listeners

190 Listeners

41 Listeners